Lori Westendorf

1.8k total citations
29 papers, 1.2k citations indexed

About

Lori Westendorf is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Lori Westendorf has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Molecular Biology. Recurrent topics in Lori Westendorf's work include Monoclonal and Polyclonal Antibodies Research (15 papers), HER2/EGFR in Cancer Research (13 papers) and Glycosylation and Glycoproteins Research (7 papers). Lori Westendorf is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (15 papers), HER2/EGFR in Cancer Research (13 papers) and Glycosylation and Glycoproteins Research (7 papers). Lori Westendorf collaborates with scholars based in United States. Lori Westendorf's co-authors include Ivan J. Stone, Django Sussman, Dennis R. Benjamin, Stephen C. Alley, Charlotte F. McDonagh, Robert P. Lyon, Martha E. Anderson, Kerry Klussman, Che‐Leung Law and Peter D. Senter and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Development.

In The Last Decade

Lori Westendorf

28 papers receiving 1.2k citations

Peers

Countries citing papers authored by Lori Westendorf

Since Specialization

Citations

This map shows the geographic impact of Lori Westendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Westendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Westendorf more than expected).

Fields of papers citing papers by Lori Westendorf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Westendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Westendorf. The network helps show where Lori Westendorf may publish in the future.

Co-authorship network of co-authors of Lori Westendorf

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Westendorf. A scholar is included among the top collaborators of Lori Westendorf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Westendorf. Lori Westendorf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47 2024 ·Molecular Cancer Therapeutics ·Matthew R. Levengood, (unknown), Xinqun Zhang, (unknown), (unknown), Lori Westendorf, Alice Chin, Arlan D. Martin, (unknown), Shawna Hengel, Hao Sun, Weiping Zeng, (unknown), (unknown), Yufei Chen, Janet H. Zheng, Caroline Karlsson, (unknown), Peter D. Senter, Shyra J. Gardai	0
2	SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications 2023 ·Molecular Cancer Therapeutics ·Robert P. Lyon, Mechthild Jonas, Christopher Frantz, Esther S. Trueblood, Roma Yumul, Lori Westendorf, (unknown), Jackie L. Stilwell, (unknown), (unknown), Vineet Kumar, Gabriela I. Patilea‐Vrana, Kerry Klussman, Maureen C. Ryan	12
3	Abstract 2906: SGN-B6A: A new MMAE ADC targeting integrin beta-6 in multiple carcinoma indications 2020 ·Cancer Research ·Robert P. Lyon, Michael Schmitt, Mechthild Jonas, (unknown), Esther S. Trueblood, Roma Yumul, Lori Westendorf, Maureen C. Ryan	2
4	Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction 2019 ·Molecular Cancer Therapeutics ·Fu Li, Michelle Ulrich, Vincent Feng-Sheng Shih, Julia H. Cochran, Joshua H. Hunter, Lori Westendorf, Jason Neale, Dennis R. Benjamin	37
5	Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability 2018 ·Protein Engineering Design and Selection ·Django Sussman, Lori Westendorf, David W. Meyer, Chris Leiske, Martha E. Anderson, Nicole M. Okeley, Stephen C. Alley, Robert P. Lyon, (unknown), (unknown), (unknown)	47
6	Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates 2017 ·Molecular Cancer Therapeutics ·Fu Li, Michelle Ulrich, Mechthild Jonas, Ivan J. Stone, (unknown), Xinqun Zhang, Lori Westendorf, Dennis R. Benjamin, Che‐Leung Law	53
7	Abstract 1285: Tumor associated macrophages can process antibody-drug conjugates and contribute to antitumor activity in preclinical xenograft models 2016 ·Cancer Research ·Li Fu, Michelle Ulrich, Mechthild Jonas, (unknown), Xinqun Zhang, Lori Westendorf, Dennis R. Benjamin, Che‐Leung Law	2
8	Abstract 2082: Fc-FcγR interaction impacts the clearance and antitumor activity of antibody-drug conjugates in NSG mice 2016 ·Cancer Research ·Fu Li, Michelle Ulrich, Joshua H. Hunter, Lori Westendorf, (unknown), (unknown), Dennis R. Benjamin, Che‐Leung Law	2
9	Abstract 2472: SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities 2015 ·Cancer Research ·Shyra J. Gardai, Angela Epp, (unknown), Lori Westendorf, May Kung Sutherland, Haley D. Neff‐LaFord, Stanford L. Peng, Che‐Leung Law	5
10	SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer 2014 ·Molecular Cancer Therapeutics ·Django Sussman, Leia M. Smith, Martha E. Anderson, (unknown), Joshua H. Hunter, Heather Kostner, Jamie B. Miyamoto, Albina Nesterova, Lori Westendorf, Heather A. Van Epps, Nancy Whiting, Dennis R. Benjamin	104
11	Development of orally active inhibitors of protein and cellular fucosylation 2013 ·Proceedings of the National Academy of Sciences ·Nicole M. Okeley, Stephen C. Alley, Martha E. Anderson, Tamar E. Boursalian, Patrick Burke, (unknown), Scott C. Jeffrey, Kerry Klussman, Che‐Leung Law, Django Sussman, Brian E. Toki, Lori Westendorf, Weiping Zeng, Xinqun Zhang, Dennis R. Benjamin, Peter D. Senter	147
12	SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML 2013 ·Blood ·May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey, Patrick Burke, Changpu Yu, Heather Kostner, Ivan J. Stone, Maureen C. Ryan, Django Sussman, Robert P. Lyon, Weiping Zeng, Kimberly H. Harrington, Kerry Klussman, Lori Westendorf, David W. Meyer, Irwin D. Bernstein, Peter D. Senter, Dennis R. Benjamin, Jonathan G. Drachman, Julie A. McEarchern	291
13	Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index 2008 ·Molecular Cancer Therapeutics ·Charlotte F. McDonagh, Kristine M. Kim, Eileen Turcott, Lindsay L. Brown, Lori Westendorf, Tiffany Feist, Django Sussman, Ivan J. Stone, Martha E. Anderson, Jamie B. Miyamoto, Robert P. Lyon, Stephen C. Alley, Hans‐Peter Gerber, Paul J. Carter	60
14	Anti-CD30 diabody-drug conjugates with potent antitumor activity 2008 ·Molecular Cancer Therapeutics ·Kristine M. Kim, Charlotte F. McDonagh, Lori Westendorf, Lindsay L. Brown, Django Sussman, Tiffany Feist, Robert P. Lyon, Stephen C. Alley, Nicole M. Okeley, Xinqun Zhang, Melissa C. Thompson, Ivan J. Stone, Hans‐Peter Gerber, Paul J. Carter	73
15	Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies 2007 ·Molecular Cancer Therapeutics ·Hans‐Peter Gerber, (unknown), Ivan J. Stone, Mechthild Jonas, (unknown), Jamie B. Miyamoto, Lindsay L. Brown, Lori Westendorf, Damon L. Meyer, Django Sussman, Paul Carter, Che‐Leung Law, Iqbal S. Grewal	2
16	Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment 2006 ·Protein Engineering Design and Selection ·Charlotte F. McDonagh, Eileen Turcott, Lori Westendorf, (unknown), Stephen C. Alley, (unknown), Jamie B. Andreyka, Ivan J. Stone, Kevin J. Hamblett, J A Francisco, Paul Carter	182
17	Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics 2005 ·Leukemia ·Charles G. Cerveny, (unknown), (unknown), (unknown), Kevin J. Hamblett, Lori Westendorf, (unknown), Joseph M. Petroziello, J A Francisco, Alan F. Wahl	45
18	A major role for zygotichunchbackin patterning theNasoniaembryo 2005 ·Development ·Mary Anne Pultz, Lori Westendorf, Samuel D. Gale, (unknown), Jeremy Lynch, Jason N. Pitt, Nick Reeves, (unknown), Stephen Small, Claude Desplan, David S. Leaf	51
19	Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer 2004 ·Oncogene ·Joseph M. Petroziello, (unknown), Lori Westendorf, Melissa C. Thompson, Charlotte F. McDonagh, Charles G. Cerveny, Che‐Leung Law, Alan F. Wahl, Paul Carter	61
20	The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics. 2004 ·Blood ·Charles G. Cerveny, Che‐Leung Law, (unknown), (unknown), Kevin J. Hamblett, Lori Westendorf, (unknown), Joseph M. Petroziello, Joseph A. Francisco, Alan F. Wahl	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact